Correction to *Lancet Oncol* 2016; 17: 883–95

Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol *2016; **17:** 883–95*—In this Article, the declaration of interests should read "JAL-M has received personal fees from reimbursement of trial-associated costs, and non-financial support from Bristol-Myers Squibb. JB reports payments to her institution, Sarah Cannon Research Institute, from Bristol-Myers Squibb, for the conduct of the trial; consulting fees (all paid to her institution and not to her personally) from Bristol Myers Squibb, Roche, Taiho Oncology, Amgen, Genentech, Merrimack, Celgene, MedImmune, Seattle Genetics, Daiichi Sankyo, Janssen, Translational Drug Development, Five Prime Therapeutics, Moderna Therapeutics, Tolero, Evelo Biosciences, Arrys Therapeutics, Forma Therapeutics, Tanabe Research Laboratories, BeiGene, Continuum Clinical, and Cerulean; payments to her institution (not to her personally) for the conduct of clinical trials on which she served as principal investigator from AbbVie, AstraZeneca, EMD Serono, Ipsen Biopharma, Incyte, Novartis, Eisai, Pfizer, Millennium, Imclone, Boston Biomedical, CALGB, Acerta Pharma, Lilly, Gilead Sciences, Leap Therapeutics, Macrogenics, OncoMed Pharmaceuticals, Takeda Pharmaceuticals, Rgenix, Novocure, Merus, NV, Blueprint Medicine, Array Biopharma, ARMO Biosciences, and Agios; JB also reports that her institution, Sarah Cannon Research Institute, conducts clinical trials and performs consulting services for several hundred companies; the companies listed above are the ones in which JB was personally involved. PAO has received consulting fees from Amgen and Bristol-Myers Squibb; and clinical trial funding from Armo Biosciences, Bristol-Myers Squibb, Merck, and MedImmune. MT has served on advisory boards and received honoraria from Eisai and Onyx. JPE has served on an advisory board and received honoraria from Roche. DJ has received consulting fees from Definiens AG, F Hoffmann-La Roche Ltd, CureVac AG, Roche Pharma AG, Novartis Pharma AG, and Novartis Oncology - Novartis Farma. MCP has received grant support from Bristol-Myers Squibb to conduct this study; personal fees from AbbVie, CelGene, Clovis Oncology, Genentech, Novartis; and grants from Novartis, OncoMed Pharmaceuticals, and Stemcentrix. DTL has received financial support from Bristol-Myers Squibb to conduct this study. FdB has served on advisory boards for and has received personal fees from Bristol-Myers Squibb, Merck Serono, MSD, Roche, and Novartis. PAA reports grants for research funding and personal fees for advisory/consultant role from Array, Bristol-Myers Squibb, and Roche-Genentech; and personal fees for advisory/consultant role from Amgen, Genmab, Idera, Immunocore, Incyte, Medimmune, Merck Serono, MSD, NewLink Genetics, Novartis, Pierre Fabre, Sandoz, Syndax, Sun Pharma, Sanofi, and Ultimovacs. LH has received research funding from AstraZeneca; served as a paid consultant for Genentech and Merck and an unpaid consultant for Bayer, Bristol-Myers Squibb, and Xcovery; and received lecture fees from Biodesix. AAm has received personal fees and grant support from Bristol-Myers Squibb. JE has received grant support from AstraZeneca, Basilea pharmaceutica, Bayer, Bristol-Myers Squibb, Celgene, Clovis, Daiichi Sankyo, Eisai, e-Therapeutics, GlaxoSmithKline, Gilead, Immunocore, Merck, Otsuka, Roche/Genentech, TC BioPharm, Verastem, and Vertex; and served on advisory boards for and received honorarium payable to the institution from Baxter, Bayer, Bristol-Myers Squibb, Celgene, Clovis, Eisai, GlaxoSmithKline, Immunova, Karus Therapeutics, Otsuka, Roche/Genentech, TC BioPharm, and Transgene/Jennerex. IC has received research grant support and personal fees from Bristol-Myers Squibb. PB has received personal fees from Bristol-Myers Squibb, Ipsen, MSD, Novartis, Orion Pharma, and Pfizer; and stock ownership from TIL Biotherapeutics. AAt has served on advisory boards and received honoraria from Bristol-Myers Squibb. PS has served as a consultant to Amgen, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline; and reports patents licensed for self to Jounce. CTH and C-SL are employed by and own stock in Bristol-Myers Squibb. OC was employed by and owned stock in Bristol-Myers Squibb. EC reports research grants and/or financial support from Boehringer-Ingelheim, Roche/Genentech, BMS, Novartis, PsiOxus, Nanobiotix Janssen, Abbvie, PharmaMar, PUMA, Sanofi, Lilly, Pfizer, Merck, Nektar, Amcure, Amgen, AstraZeneca, Principia, Bayer, CytomX, H3, Incyte, Kura, LOXO, Macrogenics, Menarini, Merck Serono, Merus, Millenium, Rigontec, Tahio, and BeuGene Tesaro; consultancy fees from Janssen-Cilag, Alkermes (and travel expenses), Seattle Genetics, Pierre Fabre, Cerulean Pharma, EUSA, Celgene, Novartis (speakers' bureau), Nanobiotix, PsiOxus Therapeutics, Abbvie, AstraZeneca, Guidepoint Global, Roche/Genentech (and travel expenses), GLG, Pfizer, Servier, Amcure, and Boehringer-Ingelheim; ownership from START (leadership), Oncoarts Associated, and International Cancer Consultants; employment from START and HM Hospitals Group (honoraria); and president and founder of NPO Foundation Intheos (Investigational Therapeutics in Oncological Sciences), outside the submitted work. All other authors declare no competing interests." This correction has been made to the online version as of Feb 1, 2019.